Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
Authors:
- Nicholas C. CullenNCNicholas C. Cullen
- The Alzheimer’s Disease Neuroimaging InitiativeTIThe Alzheimer’s Disease Neuroimaging Initiative
- Oskar HanssonOHOskar Hansson
Open Access
- 11 August 2020
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 7 (9) , 1661-1673
Abstract
Objective: To investigate the statistical power of plasma, imaging, and cognition biomarkers as Alzheimer’s disease (AD) clinical trial outcome measures.Methods: Plasma neurofilament light, structural magnetic resonance imaging, and cognition were measured longitudinally in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in control (amyloid PET or CSF Aβ42 negative [Aβ‐] with Clinical Dementia Rating scale [CDR] = 0; n = 330), preclinical AD (Aβ + with CDR = 0; n = 218) and mild AD (Aβ + with CDR = 0.5‐1; n = 697) individuals. A statistical power analysis was performed across biomarkers and groups based on longitudinal mixed effects modeling and using several different clinical trial designs.Results: For a 30‐month trial of preclinical AD, both the temporal composite and hippocampal volumes were superior to plasma neurofilament light and cognition. For an 18‐month trial of mild AD, hippocampal volume was superior to all other biomarkers. Plasma neurofilament light became more effective with increased trial duration or sampling frequency. Imaging biomarkers were characterized by high slope and low within‐subject variability, while plasma neurofilament light and cognition were characterized by higher within‐subject variability.Interpretation: MRI measures had properties that made them preferable to cognition and pNFL as outcome measures in clinical trials of early AD, regardless of cognitive status. However, pNfL and cognition can still be effective depending on inclusion criteria, sampling frequency, and response to therapy. Future trials will help to understand how sensitive pNfL and MRI are to detect downstream effects on neurodegeneration of drugs targeting amyloid and tau pathology in AD.Keywords
Funding Information
- Parkinson Research Foundation
- Skånes universitetssjukhus
- Alzheimer's Drug Discovery Foundation (RDAPB‐201809‐2016615)
- European Research Council (681712)
- Brain Foundation
- Knut och Alice Wallenbergs Stiftelse
- Hjärnfonden (FO2017‐0243)
- Strategic Research Council
- Lunds Universitet
This publication has 31 references indexed in Scilit:
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degenerationNature Medicine, 2020
- Plasma and CSF neurofilament lightNeurology, 2019
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s DiseaseNew England Journal of Medicine, 2019
- Blood neurofilament light chain as a biomarker of MS disease activity and treatment responseNeurology, 2019
- Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement DisordersJAMA Neurology, 2019
- High performance plasma amyloid-β biomarkers for Alzheimer’s diseaseNature, 2018
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional StudyEBioMedicine, 2016
- Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2015
- The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015Alzheimer's & Dementia, 2015
- Fully-Automated White Matter Hyperintensity Detection with Anatomical Prior Knowledge and without FLAIR2009